Search results
Results from the WOW.Com Content Network
A ligand binding assay (LBA) is an assay, or an analytic procedure, which relies on the binding of ligand molecules to receptors, antibodies or other macromolecules. [1] A detection method is used to determine the presence and amount of the ligand-receptor complexes formed, and this is usually determined electrochemically or through a fluorescence detection method. [2]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. [5] LAG3, which was discovered in 1990 [6] and was designated CD223 (cluster of differentiation 223) after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, [7] is a cell surface molecule with diverse biological effects on T cell function but overall has an immune ...
Lymphotoxin-alpha (LT-α) formerly known as tumor necrosis factor-beta (TNF-β) [5] [6] is a protein that in humans is encoded by the LTA gene. [7] [8] Belonging to the hematopoietic cell line, LT-α exhibits anti-proliferative activity and causes the cellular destruction of tumor cell lines. [7]
Efti – as a soluble LAG-3 protein – is an MHC class II agonist and therefore a dendritic-cell activator, causing increased antigen presentation to cytotoxic (CD8+) T cells. In the absence of antigen presentation via MHC class II molecules, efti reactivates dormant antigen-experienced memory T cells , allowing them to recognize their antigen ...
Immune stimulating antibody conjugates work by activating dendritic cells within the tumor, [3] and are capable of being delivered systemically. [4] With some patients being resistant to checkpoint inhibitors , immune stimulating antibody conjugates may be able to harness an immune response generated through the stimulation of toll-like ...
The EC 50 of the agonist is represented by the x co-ordinate that corresponds with the half-maximum of the leftmost curve. This is denoted by [A] This is denoted by [A] Half maximal effective concentration ( EC 50 ) is a measure of the concentration of a drug, antibody or toxicant which induces a biological response halfway between the baseline ...
Anti-Lan antibodies may cause transfusion reactions on subsequent exposures to Lan-positive blood, and have also been implicated in mild cases of hemolytic disease of the newborn. However, the clinical significance of the antibody is variable. The antigen was first described in 1961, and Lan was officially designated a blood group in 2012. [1] [2]